UA100866C2 - Продукт твердой дисперсии, который содержит соединения на основе n-арилмочевины - Google Patents

Продукт твердой дисперсии, который содержит соединения на основе n-арилмочевины

Info

Publication number
UA100866C2
UA100866C2 UAA201006030A UAA201006030A UA100866C2 UA 100866 C2 UA100866 C2 UA 100866C2 UA A201006030 A UAA201006030 A UA A201006030A UA A201006030 A UAA201006030 A UA A201006030A UA 100866 C2 UA100866 C2 UA 100866C2
Authority
UA
Ukraine
Prior art keywords
solid dispersion
dispersion product
aryl urea
based compounds
agent
Prior art date
Application number
UAA201006030A
Other languages
English (en)
Ukrainian (uk)
Inventor
Рудольф Шредер
Танья Хайтерманн
Original Assignee
Эбботт Гмбх Унд Ко. Кг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Гмбх Унд Ко. Кг filed Critical Эбботт Гмбх Унд Ко. Кг
Publication of UA100866C2 publication Critical patent/UA100866C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Продукт твердой дисперсии, который содержит по меньшей мере один активный агент на основе N-арилмочевин, полученный а) получением жидкой смеси, которая содержит по меньшей мере один активный агент, по меньшей мере один фармацевтически приемлемый матрицеобразующий агент, по меньшей мере одно фармацевтически приемлемое вещество и по меньшей мере один растворитель, и b) удалением растворителя(ей) из жидкой смеси с получением продукта твердой дисперсии.
UAA201006030A 2007-10-19 2008-10-17 Продукт твердой дисперсии, который содержит соединения на основе n-арилмочевины UA100866C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99961307P 2007-10-19 2007-10-19
PCT/EP2008/064073 WO2009050289A2 (en) 2007-10-19 2008-10-17 Solid dispersion product containing n-aryl urea-based compound

Publications (1)

Publication Number Publication Date
UA100866C2 true UA100866C2 (ru) 2013-02-11

Family

ID=40089072

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201006030A UA100866C2 (ru) 2007-10-19 2008-10-17 Продукт твердой дисперсии, который содержит соединения на основе n-арилмочевины

Country Status (23)

Country Link
US (1) US20090143423A1 (ru)
EP (1) EP2197426A2 (ru)
JP (1) JP2011500647A (ru)
KR (1) KR20100090689A (ru)
CN (1) CN101827585A (ru)
AR (1) AR068916A1 (ru)
AU (1) AU2008313620A1 (ru)
BR (1) BRPI0818339A2 (ru)
CA (1) CA2699335A1 (ru)
CL (1) CL2008003092A1 (ru)
CO (1) CO6270303A2 (ru)
CR (1) CR11441A (ru)
DO (1) DOP2010000114A (ru)
EC (1) ECSP10010184A (ru)
GT (1) GT201000095A (ru)
MX (1) MX2010004292A (ru)
PE (1) PE20091041A1 (ru)
RU (1) RU2010119924A (ru)
TW (1) TW200922549A (ru)
UA (1) UA100866C2 (ru)
UY (1) UY31406A1 (ru)
WO (1) WO2009050289A2 (ru)
ZA (1) ZA201002130B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8609692B2 (en) * 2008-10-17 2013-12-17 Abbvie Inc. TRPV1 antagonists
UY32180A (es) * 2008-10-17 2010-05-31 Abbott Lab Antagonistas del receptor transitorio potencial de vanilloides 1 (trpv1)
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
JP2013505210A (ja) * 2009-09-18 2013-02-14 ビーエーエスエフ ソシエタス・ヨーロピア 水への溶解性が低い物質の製剤を製造する方法
WO2012085236A1 (en) * 2010-12-23 2012-06-28 Abbott Gmbh & Co. Kg Solid retard formulations based on solid dispersions
ES2632979T3 (es) * 2011-01-10 2017-09-18 Celgene Corporation Formas de dosificación oral de {2-[(1S)-1-(3-etoxi-4-metoxi-fenil)-2-metanosulfonil-etil]-3-oxo-2,3-dihidro-1H-isoindol-4-il}-amida de ácido ciclopropanocarboxílico
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
JP5781706B2 (ja) * 2011-12-29 2015-09-24 アッヴィ・アイルランド・アンリミテッド・カンパニー Ｈｃｖ阻害剤を含む固体組成物
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
AU2014233705C1 (en) 2013-03-15 2019-10-10 Boehringer Ingelheim International Gmbh Solid oral dosage formulation of HCV inhibitor in the amorphous state
CN105358139B (zh) 2013-07-03 2020-10-16 Lts罗曼治疗方法有限公司 具有电子元件的经皮治疗系统
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
CN106456567A (zh) 2014-05-20 2017-02-22 Lts勒曼治疗系统股份公司 在经皮递送系统中调节活性剂释放的方法
JP6573913B2 (ja) * 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
ES2954087T3 (es) 2014-05-20 2023-11-20 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un mediador de interfase
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
EP3393462B8 (en) * 2015-12-22 2023-06-21 Arizona Board of Regents on behalf of the University of Arizona Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia
CN112955130A (zh) * 2018-10-30 2021-06-11 佩洛通治疗公司 包含取代茚满的固体分散体和药物组合物及其制备和使用方法
WO2021039023A1 (ja) 2019-08-23 2021-03-04 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362878A (en) * 1991-03-21 1994-11-08 Pfizer Inc. Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT)
RU94046149A (ru) * 1992-05-28 1996-11-27 Пфайзер Инк. (US) Новые n-арил и n-гетероарил производные мочевины как ингибиторы ацил кофермента а:холестерин ацил трансферазы (асат) фармацевтическая композиция, способ ингибирования (асат)
JP2002520377A (ja) * 1998-07-14 2002-07-09 イーエム インダストリーズ インコーポレイテッド ミクロ分散薬物送達システム
US7015233B2 (en) * 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
WO2005123076A2 (en) * 2004-06-08 2005-12-29 Vertex Pharmaceuticals, Inc. Pharmaceutical compositions
CA2578442A1 (en) * 2004-08-27 2006-03-09 Bayer Pharmaceuticals Corporation Pharmaceutical compositions comprising 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-phenoxy}-pyridine-2-carboxylic acid methyl amide for the treatment of cancer
CA2605183A1 (en) * 2005-04-18 2006-10-26 Rubicon Research Pvt. Ltd. Bioenhanced compositions
KR100715355B1 (ko) * 2005-09-30 2007-05-07 주식회사유한양행 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법
CA2626579A1 (en) * 2005-10-25 2007-05-03 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
WO2007066189A2 (en) * 2005-12-09 2007-06-14 Pfizer Products Inc. Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
US7745448B2 (en) * 2005-12-28 2010-06-29 Abbott Laboratories Inc. Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate
CN101378731B (zh) * 2006-02-09 2014-03-05 默沙东公司 Cetp抑制剂的聚合物制剂

Also Published As

Publication number Publication date
WO2009050289A3 (en) 2010-03-25
AR068916A1 (es) 2009-12-16
JP2011500647A (ja) 2011-01-06
BRPI0818339A2 (pt) 2015-04-22
EP2197426A2 (en) 2010-06-23
MX2010004292A (es) 2010-08-02
CN101827585A (zh) 2010-09-08
CL2008003092A1 (es) 2009-11-27
CA2699335A1 (en) 2009-04-23
AU2008313620A1 (en) 2009-04-23
US20090143423A1 (en) 2009-06-04
TW200922549A (en) 2009-06-01
ECSP10010184A (es) 2010-06-29
RU2010119924A (ru) 2011-11-27
DOP2010000114A (es) 2010-05-15
PE20091041A1 (es) 2009-08-22
WO2009050289A2 (en) 2009-04-23
GT201000095A (es) 2012-04-03
KR20100090689A (ko) 2010-08-16
CO6270303A2 (es) 2011-04-20
ZA201002130B (en) 2011-11-30
UY31406A1 (es) 2009-05-29
CR11441A (es) 2010-10-25

Similar Documents

Publication Publication Date Title
MX2010004292A (es) Producto de dispersion solida que contiene un compuesto a base de n-aril urea.
MX2010004291A (es) Producto de dispersion solida de farmacos basados en n-aril urea.
WO2010015567A3 (en) Controlled release formulations using intelligent polymers
WO2007086078A3 (en) Novel pharmaceutical compositions and process of preparation thereof
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
WO2007125103A3 (en) Benzamide glucokinase activators
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
AR055561A1 (es) Comprimidos con dispersion mejorada de la sustancia farmacologica
PL2046292T3 (pl) Preparaty eterów benzymidazolilo-pirydylowych
WO2008073138A3 (en) Terephthalamate compounds and compositions, and their use as hiv integrase inhibitors
WO2012066488A3 (en) Bridged spiro[2.4]heptane ester derivatives
WO2010021607A3 (en) Pharmaceutical formulation
PT2076119E (pt) Composição solvente incluindo pelo menos dois solventes, e formulação fitossanitária que inclua a composição referida bem como um composto activo
WO2011103610A3 (de) Pflanzenschutzmittel
HK1208441A1 (en) Fluorinated bridged spiro[2.4]heptane derivatives as alx receptor agonists
WO2009060952A1 (ja) 新規製剤
MX363699B (es) Producto de comicronizacion que comprende acetato de ulipristal.
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
TW200637826A (en) Chemical compounds
WO2010058104A3 (fr) Compositions pharmaceutiques utilisant l'inuline comme excipient de granulation
WO2007065625A3 (en) Pharmaceutical compositions of short-acting hypnotic agents in modified-release forms and the procedures to prepare the mentioned formulations
WO2007143506A3 (en) Substituted benzimidazole thiophene benzyl ether compounds
WO2010061219A3 (en) Polymorphs
WO2009150530A3 (en) Pharmaceutical composition suitable for use as foam comprising 5'-aminosalicylic acid and silicone oil
WO2008086678A3 (fr) Usage médical de lévophéncynonate comme agent neuroprotecteur